# RNN 1st Gen Model Abbott Laboratories Pharmaceutical preparations

Stock predictor AI models:
61.02% successful of 59 deals
$ 116.82 Last close price
at 18-oct-2021


Model's trade recommendations -1.50% Return for period

-6.02% Annual return

$101.03B Market Cap

β 1.50  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period -1.50%
52wk return -17.74%
52wk Range
Sortino ratio -0.51
Sharpe ratio -0.45
Norm. RMSE 0.48%
Downside risk 11.12%
Volatility 0.00%
  • 1.12 (1.94%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Abbott Laboratories (ABT) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since April 29, 2015.

Market data for ABT model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for ABT.

Model is being retrained on a daily basis.

Float 1733M
P/E 22.17
Shares Outstanding 1746M
% Held by Insiders 0.74%
% Held by Institutions 72.27%
EPS (last reported FY) $2.50
EPS (last reported Q) $0.59
EPS, estimated (last reported Q) $0.58
Total revenues $27 B
Net income $0 B